This is a study of immunosuppressed individuals living in households with and without children to assess the role of household contact with children in the transmission of SARSCoV-2 to immunocompromised individuals. Through careful collection of epidemiological data in combination with biological specimens, risk factors for SARS-CoV-2 in immunocompromised individuals will be identified. During the initial visits, informed consent will be obtained and consented participants will complete an initial questionnaire and provide biological specimens including nasal swabs, saliva and blood. Thereafter, participants will complete at-home saliva collections and questionnaires on a weekly basis for 6 months. If our research-use only SARS-CoV-2 test is positive, participants will be referred immediately for medical attention and will be followed every 3 days with nasal swabs and saliva samples and weekly blood specimens and optional rectal swabs or fresh stool collection. Additionally, participants will be contacted by telephone at 1 year for follow-up.
This is a prospective, longitudinal cohort study of immunosuppressed patients living in
households with and without children to assess the role of household contact with children in
the transmission of SARS-CoV-2 to immunocompromised patients. This study will be enrolling
both pediatric and adult patients who are immunosuppressed, as well as their household
members who agree to participate. Through careful collection of epidemiological data in
combination with biological specimens, risk factors for SARS- CoV-2 in immunocompromised
patients will be identified. During the initial study visit, informed consent will be
obtained, the study questionnaire will be completed and the participant will provide
biological specimens including nasal mid-turbinate swabs, saliva and blood. Thereafter,
participants will complete at-home saliva collections and questionnaires on a weekly basis
for 6 months. If our research-use only SARS-CoV-2 test is positive, participants will be
referred immediately to University of California at Los Angeles(UCLA) Health for medical
attention and will be followed every 3 days with nasal swabs and saliva samples, and weekly
blood specimens and optional rectal swabs or fresh stool collection. Biological specimen and
questionnaire follow-up will occur for 6 months for uninfected participants or until the of
end of viral shedding and immunologic profiling for patients infected with SARS-CoV-2,
whichever is longer. All participants will be followed at 6 months with the same baseline
measurements and then participants will be contacted by telephone at 1 year.
The clinical data and biological specimens collected in this initial study will provide will
inform and allow future studies of clinical outcomes, viral characteristics, and immune
responses to SARS-CoV-2 infection.
Inclusion Criteria:
- Immunocompromised patient followed at UCLA Health
- Immunocompromised patient >1 day old to <60 years of age
- Patient with a diagnosis of breast, lung, or colorectal cancers, lymphoma,
acute/chronic leukemia, multiple myeloma, or other solid tumors and are receiving
chemotherapy
- Patients who have received a hematopoietic stem cell transplantation within the last
year
- Patients who have received a solid organ transplantation within the last year
Exclusion Criteria:
- Immunocompromised patients with positive SARS-CoV-2 test prior to study enrollment
University of California at Los Angeles
Los Angeles, California, United States
Grace Aldrovandi, M.D., Principal Investigator
University of Califiornia at Los Angeles